ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

11:15AM-11:30AM: Abstract Number: 0872

Silencing of Schnurri-3 protects from TNF-induced bone loss and is accompanied by upregulation of type I Interferon-Stimulated Genes (ISGs) in osteoblasts.

Abstracts: Rheumatoid Arthritis – Animal Models (0867–0872)

1:00PM-1:15PM: Abstract Number: 1668

A clinically validated assay for rapid determination of type I and type II interferon activity in pediatric inflammatory diseases

Abstracts: Pediatric Rheumatology – Clinical I (1668–1673)

1:00PM-1:15PM: Abstract Number: 1674

A Phase 2, Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Individuals At-Risk for Future Rheumatoid Arthritis

Abstracts: Rheumatoid Arthritis – Treatment I: Preventative and Novel Treatments (1674–1679)

1:00PM-1:15PM: Abstract Number: 1662

Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II: Models and Mechanisms (1662–1667)

1:00PM-1:15PM: Abstract Number: 1680

Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review

Abstracts: Sjögren’s Disease – Basic & Clinical Science (1680–1685)

1:00PM-1:15PM: Abstract Number: 1650

Malondialdehyde-Acetaldehyde and Citrulline Modified Proteins are Overexpressed in Cardiac Tissues in Rheumatoid Arthritis-Associated Heart Failure and Mediate Endothelial Cell Dysfunction

Abstracts: Cytokines & Cell Trafficking (1650–1655)

1:00PM-1:15PM: Abstract Number: 1656

Risk of Serious Infection associated with non-TNF biologic initiation after Anti-TNF Use in Older Adults with Rheumatoid Arthritis

Abstracts: Health Services Research (1656–1661)

1:15PM-1:30PM: Abstract Number: 1651

Compound Heterozygosity for the Ile692del and Val726Ala Pathogenic MEFV Variants and Elevated IL-18 (CHIVE-18 syndrome) Is Distinct from Familial Mediterranean Fever (FMF) and Includes a Pronounced Response to Interferon Stimulation in Myeloid Cell Populations

Abstracts: Cytokines & Cell Trafficking (1650–1655)

1:15PM-1:30PM: Abstract Number: 1669

Development and Validation of Minimal Disease Activity and Disease Flare for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach

Abstracts: Pediatric Rheumatology – Clinical I (1668–1673)

1:15PM-1:30PM: Abstract Number: 1657

Extracting TNF Inhibitor Switching Reasons and Trajectories From Real-World Data Using Large Language Models

Abstracts: Health Services Research (1656–1661)

1:15PM-1:30PM: Abstract Number: 1681

Lymphoma and Other Malignancies in Sjögren’s Disease: Incidence, Predictive Factors, and Mortality Outcomes.

Abstracts: Sjögren’s Disease – Basic & Clinical Science (1680–1685)

1:15PM-1:30PM: Abstract Number: 1675

Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)

Abstracts: Rheumatoid Arthritis – Treatment I: Preventative and Novel Treatments (1674–1679)

1:15PM-1:30PM: Abstract Number: 1663

Tocilizumab for acute exacerbation of rheumatic disease-related interstitial lung disease: A prospective real-world study

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II: Models and Mechanisms (1662–1667)

1:30PM-1:45PM: Abstract Number: 1664

Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II: Models and Mechanisms (1662–1667)

1:30PM-1:45PM: Abstract Number: 1658

Cardiovascular Disease Risk and Risk Calculator Performance in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Abstracts: Health Services Research (1656–1661)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].